

HR 471

Ensuring Patient Access and Effective Drug Enforcement Act of 2015

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Crime and Law Enforcement

Introduced: Jan 22, 2015

Current Status: Received in the Senate and Read twice and referred to the Committee on the Judiciary.

Latest Action: Received in the Senate and Read twice and referred to the Committee on the Judiciary. (Apr 22, 2015)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/471>

Sponsor

Name: Rep. Marino, Tom [R-PA-10]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Blackburn, Marsha [R-TN-7]	R · TN		Jan 22, 2015
Rep. Chu, Judy [D-CA-27]	D · CA		Jan 22, 2015
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jan 22, 2015
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Feb 11, 2015
Rep. Collins, Doug [R-GA-9]	R · GA		Feb 11, 2015
Rep. Costello, Ryan A. [R-PA-6]	R · PA		Mar 25, 2015

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 23, 2015
Judiciary Committee	House	Referred to	Feb 19, 2015
Judiciary Committee	Senate	Referred To	Apr 22, 2015

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
114 S 483	Related bill	Apr 19, 2016: Became Public Law No: 114-145.

Ensuring Patient Access and Effective Drug Enforcement Act of 2015

(Sec. 2) Amends the Controlled Substances Act to define: (1) "factors as may be relevant to and consistent with the public health and safety," for purposes of the Attorney General's determination of whether registering an applicant to manufacture or distribute a controlled substance in schedule I or II is in the public interest, as factors that are relevant to and consistent with the findings of such Act; and (2) "imminent danger to the public health or safety," for purposes of the suspension of such a registration, to mean that in the absence of an immediate suspension order, controlled substances will continue to be distributed or dispensed by a registrant who knows or should know through fulfilling the obligations of the registrant under this Act that the dispensing is outside the usual course of professional practice, the distribution or dispensing poses a present or foreseeable risk of adverse health consequences or death due to the abuse or misuse of the controlled substances, or the controlled substances will continue to be diverted outside of legitimate distribution channels.

Requires an order to show cause as to why such a registration should not be denied, revoked, or suspended to: (1) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated; (2) direct the applicant or registrant to appear before the Attorney General at a specific place and time within 30 days after receipt of the order; and (3) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before such appearance. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modifications to such plan. Makes such requirements inapplicable to the issuance of an immediate suspension order.

(Sec. 3) Directs the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs and the Director of the Centers for Disease Control and Prevention, to submit a report identifying: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

Actions Timeline

- **Apr 22, 2015:** Received in the Senate and Read twice and referred to the Committee on the Judiciary.
- **Apr 21, 2015:** Mrs. Blackburn moved to suspend the rules and pass the bill, as amended.
- **Apr 21, 2015:** Considered under suspension of the rules. (consideration: CR H2329-2332)
- **Apr 21, 2015:** DEBATE - The House proceeded with forty minutes of debate on H.R. 471.
- **Apr 21, 2015:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H2329)
- **Apr 21, 2015:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H2329)
- **Apr 21, 2015:** Motion to reconsider laid on the table Agreed to without objection.
- **Apr 20, 2015:** Reported by the Committee on Energy and Commerce. H. Rept. 114-85, Part I.
- **Apr 20, 2015:** Committee on the Judiciary discharged.
- **Apr 20, 2015:** Placed on the Union Calendar, Calendar No. 63.
- **Feb 19, 2015:** Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
- **Jan 23, 2015:** Referred to the Subcommittee on Health.
- **Jan 22, 2015:** Introduced in House
- **Jan 22, 2015:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.